Skip to main content

Table 2 Clinicopathological features and grade of giant insulinomas in reports published since 2001

From: Giant insulinoma: report of a case and review of published reports

Author [ref]/year

Age

Sex

Size (cm)

Location

Surgery

Ki-67 (%)

Mitosis

Differentiation

Grade

Meta site at diagnosis

Recurrences

Follow-up (months)

Konno [14]/2001

40

F

10.5

Tail

DP, S

<2

NA

NA

1

None

None

NDR (24)

Mittendorf [6]/2005

65

F

9

Tail

Tumor resection

>2

<1

W

2

None

None

NDR (6)

Esteban [12]/2008

57

F

10

Tail

DP

20

NA

W

NEC

None

None

NDR (31)

Rega [12]/2009

60

M

15

Body/tail

DP, S

5.4

NA

WDEC

2

Surround, LN

None

NDR (3)

Sugiyama [7]/2010

50

M

12

Head

PD

1–2

1

W

1

Surround

None

NDR (12)

Matkari [12]/2010

32

M

11

Head

E

>2

NA

W

2

None

None

NDR (12)

Pramodh [12]/2010

81

M

9.8

NA

NO

<5

NA

WDEC

2

None

None

DOD (NA)

Oberheim [21]/2011

58

F

13.5

Head/body

PpPD

<1

1

W

1

None

None

NDR (12)

Callacondo [12]/2013

67

F

15

Tail

DP, S, RLM

<1

<1

W

1

Liver

Liver

AD (60)

Callacondo [12]/2013

63

M

10

Tail

DP, S

<2

5

W

1

LN

Liver

NDR (43)

Callacondo [12]/2013

38

M

11

Tail

DP, S, RLM

<2

3

W

2

Spleen, liver

Liver

DMD (156)

Ielpo [13]/2013

57

F

14

Tail

DP

>20

NA

Por

NEC

NA

None

NDR (72)

Eguchi [16]/2013

73

F

12

Tail

DP, S

NA

NA

NA

1

None

NA

NDR (4)

Fenech [17]/2013

76

F

16

Tail

DP, S

NA

<2

W

1

Surround

None

NA

Present case/2014

71

M

15

Head

SSpPD

>20

>20

Por

NEC

Surround, LN, duodenum

None

NDR (24)

Karavias [5]/2015

75

F

17

Body/tail

DP, S, RMD

NA

10

NA

2

Lt-kidney, Lt adrenal, PALN, liver, omentum

None

NDR (60)

Vasikasin [18]/2016

15

M

12.5

Tail

DP, S

1–2

3–4

NA

1

None

None

NDR (6)

Martino [19]/2016

49

F

21

Head/body/tail

Debulking

>15

15

NA

2

Surround, LN, liver, axillary, and mediastinal

Remnant

AD (36)

  1. Ki-67 Ki-67 index, Mitosis mitoses per 10 high-power fields, Meta Site metastatic sites, DP distal pancreatectomy, S splenectomy, NA not available, W well-differentiated neuroendocrine tumor, NDR no disease recurrence, NEC neuroendocrine carcinoma, WDEC well-differentiated neuroendocrine carcinoma, Surround surrounding adipose tissue, LN lymph node, PD pancreaticoduodenectomy, E enuclation, NO no operation, DOD died of other disease, PpPD pylorous-preserving PD, RLM resection of liver metastases, AD alive with disease, DMD died of metastatic disease, Por poorly differentiated neuroendocrine tumor, SSpPD subtotal stomach-preserving PD, PALN para-aorta LN, Debulking total pancreatectomy with splenectomy, partial gastrectomy, and cholecystectomy, RMD resection of metastatic diseases, Remnant remnant liver, axillary, and mediastinal metastases